Harley-Davidson Recalls Certain 2014 Touring Motorcycles


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Harley-Davidson (NYSE: HOG) is acting quickly to address potential safety issues by voluntarily recalling certain 2014 Touring motorcycles equipped with a hydraulic clutch system that may pose a safety issue for riders and/or passengers. The recalls include a Do Not Ride notice to owners and a Do Not Deliver notice to Harley-Davidson dealers until the motorcycle is fixed."The safety of our customers is our highest priority," said Tony Wilcox, Harley-Davidson General Manager of Motorcycle New Product Delivery. "We have identified potential safety issues and are moving quickly to notify our customers and dealers. The inspection and repair of these motorcycles is extremely important, so it's critical that our customers with affected vehicles contact their dealers immediately. We apologize for this circumstance. The company is committed to correcting the issues and providing customers with the quality experience and service they expect."The recalls affect 25,185 Touring motorcycles, models FLHTCU, FLHTK, FLHTP, FLHX, FLHXS, FLHTKSE and FLHRSE, and 3,861 Softail® CVOs and Trikes, models FLHTCUTG, FXSBSE and FLSTNSE, built between May 3, 2013, and Oct. 14, 2013.  Some of these motorcycles may exhibit a condition in which the hydraulic clutch system may lose the

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: NewsGuidanceContractsFDAGlobal